Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer's Disease
Artikel i vetenskaplig tidskrift, 2013

The discovery of drugs for Alzheimer's disease (AD) therapy that can also permeate the blood brain barrier (BBB) is very difficult owing to its specificity and restrictive nature. The BBB disruption or the administration of the drug directly into the brain is not an option due to toxic effects and low diffusion of the therapeutic molecule in the brain parenchyma. A promising approach for drug systemic delivery to the central nervous system is the use of nanosized carriers. The therapeutic potential of certain nanopharmaceuticals for AD has already been demonstrated in vivo after systemic delivery. They are based on i) conjugates of drug and monoclonal antibodies against BBB endogenous receptors; ii) cationized or end terminal protected proteins/peptides; iii) liposomes and polymeric nanoparticles coated with polysorbate 80, cationic macromolecules or antibodies against BBB receptors/amyloid beta-peptides. Optimization and further validation of these systems are needed.

parenteral route administration

Brain drug-targeting

therapeutic peptides


Alzheimer's disease

blood brain barrier

monoclonal antibodies

polymeric nanoparticles


Sandra Rocha

Chalmers, Kemi- och bioteknik, Fysikalisk kemi

Current Pharmaceutical Design

1381-6128 (ISSN)

Vol. 19 37 6635-6646


Nanovetenskap och nanoteknik (2010-2017)

Livsvetenskaper och teknik (2010-2018)


Farmaceutisk vetenskap





Mer information